Payment overview · 2025
General Payments
$1,295.46
39 reported records · 13 companies
Healthcare provider profile · identity verified
Michael E Posey, MD
Allopathic & Osteopathic Physicians|Internal Medicine · GERMANTOWN, TN · NPI 1194700146
Verified facts
What the public records show
CMS Open Payments records show Michael E Posey, MD received $1,295.46 in general payments during 2025 across 39 reported records.
AstraZeneca Pharmaceuticals LP accounted for 20.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 114 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $266.09 | 20.5% | 3 | 2025 |
| C2N Diagnostics, LLC | Unresolved — no canonical attribution shown | $244.49 | 18.9% | 7 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $221.34 | 17.1% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $119.52 | 9.2% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $116.02 | 9.0% | 6 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $100.91 | 7.8% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $61.18 | 4.7% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $46.36 | 3.6% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $31.02 | 2.4% | 2 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $24.88 | 1.9% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $24.74 | 1.9% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $23.76 | 1.8% | 1 | 2025 |
| HEARTFLOW, INC. | Unresolved — no canonical attribution shown | $15.15 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,295.46 | 39 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $266.09 | 3 | 2025 |
Source payment records
|
|||||
| PRECIVITYAD2 Normalized: precivityad2 |
Device | C2N Diagnostics, LLC | $244.49 | 7 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $119.52 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $116.02 | 6 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $112.84 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $108.50 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $108.50 | 5 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $100.91 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $61.18 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $46.36 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $31.02 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $28.39 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $24.88 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $24.88 | 1 | 2025 |
Source payment records
|
|||||
| DALVANCE Normalized: dalvance |
Drug | ABBVIE INC. | $24.74 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $17.41 | 1 | 2025 |
Source payment records
|
|||||
| FFRct Normalized: ffrct |
Device | HEARTFLOW, INC. | $15.15 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $12.48 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 45 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
66 | 14 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
49 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
114 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 264 | 86 |
| Amlodipine Besylate | Amlodipine Besylate | 224 | 76 |
| Fenofibric Acid | Fenofibric Acid (Choline) | 155 | 47 |
| Ezetimibe | Ezetimibe | 129 | 40 |
| Eliquis | Apixaban | 127 | 20 |
| Levoxyl | Levothyroxine Sodium | 118 | 41 |
| Mounjaro | Tirzepatide | 114 | 17 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 106 | 22 |
| Alprazolam | Alprazolam | 100 | 17 |
| Montelukast Sodium | Montelukast Sodium | 99 | 41 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 97 | 31 |
| Gabapentin | Gabapentin | 96 | 33 |
| Tamsulosin Hcl | Tamsulosin Hcl | 94 | 26 |
| Metformin Hcl Er | Metformin Hcl | 93 | 32 |
| Nebivolol Hcl | Nebivolol Hcl | 79 | 27 |
| Levothyroxine Sodium | Levothyroxine Sodium | 78 | 29 |
| Tramadol Hcl | Tramadol Hcl | 75 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 75 | 14 |
| Meloxicam | Meloxicam | 73 | 24 |
| Linzess | Linaclotide | 66 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 66 | 18 |
| Moxifloxacin Hcl | Moxifloxacin Hcl | 61 | 40 |
| Tizanidine Hcl | Tizanidine Hcl | 61 | 19 |
| Clonazepam | Clonazepam | 60 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 58 | 22 |
| Trazodone Hcl | Trazodone Hcl | 55 | 18 |
| Repatha Sureclick | Evolocumab | 54 | suppressed |
| Bupropion Xl | Bupropion Hcl | 53 | 18 |
| Lorazepam | Lorazepam | 53 | 11 |
| Pregabalin | Pregabalin | 53 | 21 |
| Vilazodone Hcl | Vilazodone Hcl | 53 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 49 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 49 | 13 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 46 | 13 |
| Pantoprazole Sodium | Pantoprazole Sodium | 46 | 19 |
| Ozempic | Semaglutide | 45 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 44 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 44 | 14 |
| Bumetanide | Bumetanide | 43 | 15 |
| Fenofibrate | Fenofibrate Nanocrystallized | 40 | 11 |
| Dutasteride | Dutasteride | 39 | 12 |
| Midodrine Hcl | Midodrine Hcl | 39 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 39 | 12 |
| Solifenacin Succinate | Solifenacin Succinate | 37 | 12 |
| Buspirone Hcl | Buspirone Hcl | 36 | 17 |
| Spironolactone | Spironolactone | 36 | 11 |
| Clindamycin Hcl | Clindamycin Hcl | 35 | 32 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 34 | suppressed |
| Trulicity | Dulaglutide | 33 | suppressed |
| Losartan Potassium | Losartan Potassium | 31 | 11 |
| Ondansetron Odt | Ondansetron | 30 | 22 |
| Omeprazole | Omeprazole | 29 | 11 |
| Potassium Chloride | Potassium Chloride | 29 | 12 |
| Celecoxib | Celecoxib | 28 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 28 | suppressed |
| Niacin Er | Niacin | 27 | suppressed |
| Synthroid | Levothyroxine Sodium | 27 | suppressed |
| Levofloxacin | Levofloxacin | 26 | 23 |
| Fluoxetine Hcl | Fluoxetine Hcl | 25 | suppressed |
| Mupirocin | Mupirocin | 25 | 11 |
| Trandolapril | Trandolapril | 25 | suppressed |
| Carvedilol | Carvedilol | 24 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 19 |
| Belsomra | Suvorexant | 23 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 23 | suppressed |
| Furosemide | Furosemide | 23 | 11 |
| Jardiance | Empagliflozin | 23 | suppressed |
| Topiramate | Topiramate | 23 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 22 | suppressed |
| Methylprednisolone | Methylprednisolone | 22 | 16 |
| Metoprolol Succinate | Metoprolol Succinate | 22 | 11 |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 20 | suppressed |
| Rivastigmine | Rivastigmine | 20 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 20 | suppressed |
| Aripiprazole | Aripiprazole | 19 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 19 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 19 | 11 |
| Cephalexin | Cephalexin | 18 | suppressed |
| Diazepam | Diazepam | 18 | suppressed |
| Famotidine | Famotidine | 18 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 18 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 16 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 16 | suppressed |
| Indapamide | Indapamide | 16 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 16 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 16 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Clonidine | Clonidine | 15 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 15 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 15 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 15 | suppressed |
| Metformin Hcl | Metformin Hcl | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Eszopiclone | Eszopiclone | 14 | suppressed |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Cefdinir | Cefdinir | 13 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 13 | suppressed |
| Lisinopril | Lisinopril | 13 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 13 | suppressed |
| Finasteride | Finasteride | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | 11 |
| Trintellix | Vortioxetine Hydrobromide | 12 | suppressed |
| Xifaxan | Rifaximin | 12 | suppressed |
| Allopurinol | Allopurinol | 11 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 11 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,295.46 · 39 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, CAPVAXIVE, DALVANCE, EVENITY, FFRct, Fluad, Flucelvax, Korlym, LEQVIO, OTEZLA, Ozempic, PRECIVITYAD2, REPATHA, Rybelsus, VERQUVO, ZEPBOUND, ZORYVE | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error